Cited 24 times in
Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명희 | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | 남기택 | - |
dc.contributor.author | 오지훈 | - |
dc.contributor.author | 이지연 | - |
dc.date.accessioned | 2020-12-11T07:46:18Z | - |
dc.date.available | 2020-12-11T07:46:18Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180651 | - |
dc.description.abstract | Approximately 70% of breast cancers are estrogen receptor (ER)-positive and treated with endocrine therapy. A commonly used treatment agent, tamoxifen, shows high efficacy for improving prognosis. However, approximately one-third of patients treated with tamoxifen develop resistance to this drug. Here, we investigated the function of general control non-derepressible 5 (GCN5) and its downstream effectors in tamoxifen-resistant (TamR) breast cancer. TamR-MCF7 breast cancer cells maintained high GCN5 levels due to its attenuated proteasomal degradation. GCN5 overexpression upregulated amplified in breast cancer 1 (AIB1) expression, resulting in decreased p53 stability and tamoxifen resistance. Conversely, the sensitivity of GCN5-AIB1-overexpressing MCF7 cells to tamoxifen was restored by forced p53 expression. An in vivo study demonstrated a positive correlation between GCN5 and AIB1 and their contribution to tamoxifen resistance. We concluded that GCN5 promotes AIB1 expression and tamoxifen resistance in breast cancer by reducing p53 levels, suggesting the utility of GCN5 and its downstream effectors as therapeutic targets to either prevent or overcome tamoxifen resistance in breast cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Ireland | - |
dc.relation.isPartOf | CANCER LETTERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anatomy (해부학교실) | - |
dc.contributor.googleauthor | Ji Hoon Oh | - |
dc.contributor.googleauthor | Ji-Yeon Lee | - |
dc.contributor.googleauthor | Kwang H Kim | - |
dc.contributor.googleauthor | Clara Yuri Kim | - |
dc.contributor.googleauthor | Da Som Jeong | - |
dc.contributor.googleauthor | Yejin Cho | - |
dc.contributor.googleauthor | Ki Taek Nam | - |
dc.contributor.googleauthor | Myoung Hee Kim | - |
dc.identifier.doi | 10.1016/j.canlet.2020.09.017 | - |
dc.contributor.localId | A00432 | - |
dc.contributor.localId | A05900 | - |
dc.contributor.localId | A01243 | - |
dc.contributor.localId | A02400 | - |
dc.contributor.localId | A03194 | - |
dc.relation.journalcode | J00448 | - |
dc.identifier.eissn | 1872-7980 | - |
dc.identifier.pmid | 32987137 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0304383520304894 | - |
dc.subject.keyword | Histone acetyltransferase | - |
dc.subject.keyword | KAT2A | - |
dc.subject.keyword | NCOA3 | - |
dc.subject.keyword | p21 | - |
dc.subject.keyword | p53 | - |
dc.contributor.alternativeName | Kim, Myoung Hee | - |
dc.contributor.affiliatedAuthor | 김명희 | - |
dc.contributor.affiliatedAuthor | 김유리 | - |
dc.contributor.affiliatedAuthor | 남기택 | - |
dc.contributor.affiliatedAuthor | 오지훈 | - |
dc.contributor.affiliatedAuthor | 이지연 | - |
dc.citation.volume | 495 | - |
dc.citation.startPage | 145 | - |
dc.citation.endPage | 155 | - |
dc.identifier.bibliographicCitation | CANCER LETTERS, Vol.495 : 145-155, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.